Randomized Phase II Study Comparing Cabozantinib (NSC 761968) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma

Trial Profile

Randomized Phase II Study Comparing Cabozantinib (NSC 761968) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2017

At a glance

  • Drugs Cabozantinib (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms CABOSUN
  • Most Recent Events

    • 09 Sep 2017 Results from this trial have been presented at the European Society for Medical Oncology (ESMO) 2017 Congress, according to an Exelixis media release.
    • 09 Sep 2017 Results published in an Exelixis media release.
    • 08 Sep 2017 According to an Ipsen media release, based on results of this trial the European Medicines Agency (EMA) has validated the application for variation to the Cabometyx (cabozantinib) marketing authorization for the addition of a new indication in first-line treatment of advanced renal cell carcinoma.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top